Insights On Pharma Logistics

  1. How Our Recent Innovative Solutions Meet Today's Supply Chain Challenges 3/25/2025

    When advanced therapy organizations place innovation at the heart of their strategy for overcoming supply chain challenges, they ultimately prioritize the most important stakeholder — the waiting patient.

  2. Supply-Chain Statistics And Realistic Outsourcing Options 3/12/2025

    Kishore Hotha, President, Dr. Hotha’s Life Sciences, provides some telling stats that should inform outsourcing decision-making in the coming months… and perhaps years.

  3. Remind Me: Why Are We At Biotech War With China? 3/12/2025

    It’s hard to focus on the issues that precipitated the challenges and proscribed solutions to so much of our supply chain being in China. IP was (and should be) at the center of the discussion.

  4. Good 'Supplier Hygiene' Before And After COVID And The BIOSECURE Act 3/12/2025

    Can you recall the fundamentals of outsourcing development and manufacturing five or 10 years ago, if you were in the industry then? Our panel can, and it’s instructive to take the trip back in time.

  5. Smaller Biotechs Take Bigger Hits 3/12/2025

    Our panel of experienced biopharma executives explain the different effects on trade wars or supply-chain disruptions with Big Pharma and smaller drug development organizations.

  6. Can We Actually Decouple US-China Supply-Chain Integration? 3/12/2025

    The realities in 2024 suggest the answer is no, and our panel of speakers detail why that is the right answer.

  7. The Costs Of Disengagement From China 3/12/2025

    If we ever did implement (suffer through?) some rather large-scale “disengagement” between the U.S. and China in the biopharma industry realm, what costs would we incur?

  8. Back To Supply-Chain And Outsourcing Basics 3/12/2025

    Vince Kosewski, KALA BIO, and Kishore Hotha, Dr. Hotha’s Life Sciences, remind us that our recent outsourcing fears should remind us of the fundamentals for approaching supply-chain decision-making.

  9. The BIOSECURE Act Will Be Back… With A Dose Of Tariffs! 3/12/2025

    Biopharma executives Robert Discordia, CEO, Equulus Therapeutics, and Reza Oliyai, CEO, Oliyai Consulting, agree we may not have seen the last of the Act… or tariffs to compound industry challenges.

  10. Update On BIOSECURE Act… And Other Supply-Chain Concerns 3/12/2025

    Chief Editor Louis Garguilo provides a succinct update on the Act, and broadens the discussion to other challenges on the horizon.